Vasundhara Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vasundhara Sharma has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Inga
University of Trento
3 shared publications - Shweta Sharma
Dept. of Microbiology, Teerthanker Mahaveer Medical College & Research centre, Moradabad, Uttar Pradesh, India
3 shared publications - Alessandra Bisio
Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy
2 shared publications Imran Ahamad
Dept. of Microbiology, Teerthanker Mahaveer Medical College & Research centre, Moradabad, Uttar Pradesh, India
2 shared publicationsSara Zaccara
2 shared publicationsUmar Farooq
2 shared publications
Latest Publications
- Open Access
- 15 February 2022
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Medical Microbiology and Tropical Diseases
- Vol. 8 (1) , 43-45
Occurrence of dengue infected patients in a tertiary care centre
Occurrence of dengue infected patients in a tertiary care centre - IJMMTD- Print ISSN No: - 2581-4753 Online ISSN No:- 2581-4761 Article DOI No:- 10.18231/j.ijmmtd.2022.009, IP International Journal of Medical Microbiology and Tropical Diseases-IP Int J Med Microbiol Trop Dis
- 15 February 2022
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Medical Microbiology and Tropical Diseases
- Vol. 8 (1) , 43-45
Open AccessOccurrence of dengue infected patients in a tertiary care centre
Occurrence of dengue infected patients in a tertiary care centre - IJMMTD- Print ISSN No: - 2581-4753 Online ISSN No:- 2581-4761 Article DOI No:- 10.18231/j.ijmmtd.2022.009, IP International Journal of Medical Microbiology and Tropical Diseases-IP Int J Med Microbiol Trop Dis
- Open Access
- 15 November 2021
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Medical Microbiology and Tropical Diseases
- Vol. 7 (4) , 288-291
Comparision of bacterial urinary tract infection in catheterised and non catheterised patients
Comparision of bacterial urinary tract infection in catheterised and non catheterised patients - IJMMTD- Print ISSN No: - 2581-4753 Online ISSN No:- 2581-4761 Article DOI No:- 10.18231/j.ijmmtd.2021.059, IP International Journal of Medical Microbiology and Tropical Diseases-IP Int J Med Microbiol Trop Dis
- 15 November 2021
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Medical Microbiology and Tropical Diseases
- Vol. 7 (4) , 288-291
Open AccessComparision of bacterial urinary tract infection in catheterised and non catheterised patients
Comparision of bacterial urinary tract infection in catheterised and non catheterised patients - IJMMTD- Print ISSN No: - 2581-4753 Online ISSN No:- 2581-4761 Article DOI No:- 10.18231/j.ijmmtd.2021.059, IP International Journal of Medical Microbiology and Tropical Diseases-IP Int J Med Microbiol Trop Dis
- Open Access
- 15 March 2021
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Medical Microbiology and Tropical Diseases
- Vol. 7 (1) , 32-36
Occurrence of malaria positive cases and their association with serum creatinine and blood urea in different age group
Occurrence of malaria positive cases and their association with serum creatinine and blood urea in different age group - IJMMTD- Print ISSN No: - 2581-4753 Online ISSN No:- 2581-4761 Article DOI No:- 10.18231/j.ijmmtd.2021.008, IP International Journal of Medical Microbiology and Tropical Diseases-IP Int J Med Microbio
- 15 March 2021
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Medical Microbiology and Tropical Diseases
- Vol. 7 (1) , 32-36
Open AccessOccurrence of malaria positive cases and their association with serum creatinine and blood urea in different age group
Occurrence of malaria positive cases and their association with serum creatinine and blood urea in different age group - IJMMTD- Print ISSN No: - 2581-4753 Online ISSN No:- 2581-4761 Article DOI No:- 10.18231/j.ijmmtd.2021.008, IP International Journal of Medical Microbiology and Tropical Diseases-IP Int J Med Microbio
- 16 January 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (3) , 191-207
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms
Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability, and has been implicated in JAK2-driven diseases best exemplified by Myeloproliferative Neoplasms (MPNs). Using novel classes of highly selective HDAC inhibitors and genetically deficient mouse models, here we report that HDAC11 rather than HDAC6 is necessary for the proliferation and survival of oncogenic JAK2-driven MPN cells and patient samples. Notably, HDAC11 is variably expressed in primitive stem cells and is expressed largely upon lineage commitment. While dispensable for normal homeostatic hematopoietic stem and progenitor cell differentiation based on chimeric BM reconstitution, Hdac11 deficiency significantly reduced the abnormal megakaryocyte population, improved splenic architecture, reduced fibrosis and increased survival in the MPLW515L-MPN mouse model during primary and secondary transplantation. Therefore, inhibitors of HDAC11 are an attractive therapy for treating MPN patients. While JAK2 inhibitor therapy provides substantial clinical benefit in MPN patients, the identification of alternative therapeutic targets is needed to reverse MPN pathogenesis and control malignant hematopoiesis. This work establishes HDAC11 as a unique type of target molecule having therapeutic potential in MPN.
- 16 January 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (3) , 191-207
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms
Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability, and has been implicated in JAK2-driven diseases best exemplified by Myeloproliferative Neoplasms (MPNs). Using novel classes of highly selective HDAC inhibitors and genetically deficient mouse models, here we report that HDAC11 rather than HDAC6 is necessary for the proliferation and survival of oncogenic JAK2-driven MPN cells and patient samples. Notably, HDAC11 is variably expressed in primitive stem cells and is expressed largely upon lineage commitment. While dispensable for normal homeostatic hematopoietic stem and progenitor cell differentiation based on chimeric BM reconstitution, Hdac11 deficiency significantly reduced the abnormal megakaryocyte population, improved splenic architecture, reduced fibrosis and increased survival in the MPLW515L-MPN mouse model during primary and secondary transplantation. Therefore, inhibitors of HDAC11 are an attractive therapy for treating MPN patients. While JAK2 inhibitor therapy provides substantial clinical benefit in MPN patients, the identification of alternative therapeutic targets is needed to reverse MPN pathogenesis and control malignant hematopoiesis. This work establishes HDAC11 as a unique type of target molecule having therapeutic potential in MPN.
- Open Access
- 10 November 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (63) , 106352-106368
WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression
WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression
- 10 November 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (63) , 106352-106368
Open AccessWEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression
WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression
- Open Access
- 27 September 2016
- Published by Oxford University Press (OUP) in FEMS Yeast Research
- Vol. 16 (7)
Human transcription factors in yeast: the fruitful examples of P53 and NF-кB
The observation that human transcription factors (TFs) can function when expressed in yeast cells has stimulated the development of various functional assays to investigate (i) the role of binding site sequences (herein referred to as response elements, REs) in transactivation specificity, (ii) the impact of polymorphic nucleotide variants on transactivation potential, (iii) the functional consequences of mutations in TFs and (iv) the impact of cofactors or small molecules. These approaches have found applications in basic as well as applied research, including the identification and the characterisation of mutant TF alleles from clinical samples. The ease of genome editing of yeast cells and the availability of regulated systems for ectopic protein expression enabled the development of quantitative reporter systems, integrated at a chosen chromosomal locus in isogenic yeast strains that differ only at the level of a specific RE targeted by a TF or for the expression of distinct TF alleles. In many cases, these assays were proven predictive of results in higher eukaryotes. The potential to work in small volume formats and the availability of yeast strains with modified chemical uptake have enhanced the scalability of these approaches. Next to well-established one-, two-, three-hybrid assays, the functional assays with non-chimeric human TFs enrich the palette of opportunities for functional characterisation. We review ∼25 years of research on human sequence-specific TFs expressed in yeast, with an emphasis on the P53 and NF-кB family of proteins, highlighting outcomes, advantages, challenges and limitations of these heterologous assays.
- 27 September 2016
- Published by Oxford University Press (OUP) in FEMS Yeast Research
- Vol. 16 (7)
Open AccessHuman transcription factors in yeast: the fruitful examples of P53 and NF-кB
The observation that human transcription factors (TFs) can function when expressed in yeast cells has stimulated the development of various functional assays to investigate (i) the role of binding site sequences (herein referred to as response elements, REs) in transactivation specificity, (ii) the impact of polymorphic nucleotide variants on transactivation potential, (iii) the functional consequences of mutations in TFs and (iv) the impact of cofactors or small molecules. These approaches have found applications in basic as well as applied research, including the identification and the characterisation of mutant TF alleles from clinical samples. The ease of genome editing of yeast cells and the availability of regulated systems for ectopic protein expression enabled the development of quantitative reporter systems, integrated at a chosen chromosomal locus in isogenic yeast strains that differ only at the level of a specific RE targeted by a TF or for the expression of distinct TF alleles. In many cases, these assays were proven predictive of results in higher eukaryotes. The potential to work in small volume formats and the availability of yeast strains with modified chemical uptake have enhanced the scalability of these approaches. Next to well-established one-, two-, three-hybrid assays, the functional assays with non-chimeric human TFs enrich the palette of opportunities for functional characterisation. We review ∼25 years of research on human sequence-specific TFs expressed in yeast, with an emphasis on the P53 and NF-кB family of proteins, highlighting outcomes, advantages, challenges and limitations of these heterologous assays.
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75 (15) , 419
Abstract 419: Cooperative interactions between p53 and NFκB enhance cell plasticity
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75 (15) , 419
Abstract 419: Cooperative interactions between p53 and NFκB enhance cell plasticity
- Open Access
- 6 July 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (7) , e0130170
Quantitative Analysis of NF-κB Transactivation Specificity Using a Yeast-Based Functional Assay
The NF-κB transcription factor family plays a central role in innate immunity and inflammation processes and is frequently dysregulated in cancer. We developed an NF-κB functional assay in yeast to investigate the following issues: transactivation specificity of NF-κB proteins acting as homodimers or heterodimers; correlation between transactivation capacity and in vitro DNA binding measurements; impact of co-expressed interacting proteins or of small molecule inhibitors on NF-κB-dependent transactivation. Full-length p65 and p50 cDNAs were cloned into centromeric expression vectors under inducible GAL1 promoter in order to vary their expression levels. Since p50 lacks a transactivation domain (TAD), a chimeric construct containing the TAD derived from p65 was also generated (p50TAD) to address its binding and transactivation potential. The p50TAD and p65 had distinct transactivation specificities towards seventeen different κB response elements (κB-REs) where single nucleotide changes could greatly impact transactivation. For four κB-REs, results in yeast were predictive of transactivation potential measured in the human MCF7 cell lines treated with the NF-κB activator TNFα. Transactivation results in yeast correlated only partially with in vitro measured DNA binding affinities, suggesting that features other than strength of interaction with naked DNA affect transactivation, although factors such as chromatin context are kept constant in our isogenic yeast assay. The small molecules BAY11-7082 and ethyl-pyruvate as well as expressed IkBα protein acted as NF-κB inhibitors in yeast, more strongly towards p65. Thus, the yeast-based system can recapitulate NF-κB features found in human cells, thereby providing opportunities to address various NF-κB functions, interactions and chemical modulators.
- 6 July 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (7) , e0130170
Open AccessQuantitative Analysis of NF-κB Transactivation Specificity Using a Yeast-Based Functional Assay
The NF-κB transcription factor family plays a central role in innate immunity and inflammation processes and is frequently dysregulated in cancer. We developed an NF-κB functional assay in yeast to investigate the following issues: transactivation specificity of NF-κB proteins acting as homodimers or heterodimers; correlation between transactivation capacity and in vitro DNA binding measurements; impact of co-expressed interacting proteins or of small molecule inhibitors on NF-κB-dependent transactivation. Full-length p65 and p50 cDNAs were cloned into centromeric expression vectors under inducible GAL1 promoter in order to vary their expression levels. Since p50 lacks a transactivation domain (TAD), a chimeric construct containing the TAD derived from p65 was also generated (p50TAD) to address its binding and transactivation potential. The p50TAD and p65 had distinct transactivation specificities towards seventeen different κB response elements (κB-REs) where single nucleotide changes could greatly impact transactivation. For four κB-REs, results in yeast were predictive of transactivation potential measured in the human MCF7 cell lines treated with the NF-κB activator TNFα. Transactivation results in yeast correlated only partially with in vitro measured DNA binding affinities, suggesting that features other than strength of interaction with naked DNA affect transactivation, although factors such as chromatin context are kept constant in our isogenic yeast assay. The small molecules BAY11-7082 and ethyl-pyruvate as well as expressed IkBα protein acted as NF-κB inhibitors in yeast, more strongly towards p65. Thus, the yeast-based system can recapitulate NF-κB features found in human cells, thereby providing opportunities to address various NF-κB functions, interactions and chemical modulators.
- Open Access
- 21 October 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (23) , 12111-12125
Cooperative interactions between p53 and NFκB enhance cell plasticity
Cooperative interactions between p53 and NFB enhance cell plasticity Cooperative interactions between p53 and NFκB enhance cell plasticity
- 21 October 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (23) , 12111-12125
Open AccessCooperative interactions between p53 and NFκB enhance cell plasticity
Cooperative interactions between p53 and NFB enhance cell plasticity Cooperative interactions between p53 and NFκB enhance cell plasticity